Market Cap 528.51M
Revenue (ttm) 64.38M
Net Income (ttm) -56.42M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -87.64%
Debt to Equity Ratio 0.00
Volume 35,019
Avg Vol 289,812
Day's Range N/A - N/A
Shares Out 50.00M
Stochastic %K 43%
Beta -0.09
Analysts Strong Sell
Price Target $17.00

Company Profile

Theravance Biopharma, Inc., a biopharmaceutical company, develops and commercializes of medicines in the United States. It offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD). The company's product includes Ampreloxetine, an investigational norepinephrine reuptake inhibitor that has completed Phase III study for neurogenic orthostatic hypotension; and TRELEGY for the treatment of COPD and asthma. It has a str...

Industry: Biotechnology
Sector: Healthcare
Phone: 650-808-6000
Address:
901 Gateway Boulevard, South San Francisco, United States
JarvisFlow
JarvisFlow Jun. 17 at 11:30 AM
Jones Trading updates rating for Theravance Biopharma ( $TBPH ) to Buy, target set at 24.
0 · Reply
ZacksResearch
ZacksResearch Jun. 3 at 4:41 PM
$TBPH pops 22% on $225M royalty sale to GSK 🔥 Theravance is offloading its last chunk of Trelegy royalties — locking in major cash as part of the deal. What this means for the future of TBPH 👉 https://www.zacks.com/stock/news/2483631/tbph-to-sell-remaining-trelegy-royalty-interest-to-gsk-stock-rises?cid=sm-stocktwits-2-2483631-teaser&ADID=SYND_STOCKTWITS_TWEET_2_2483631_TEASER
0 · Reply
ZacksResearch
ZacksResearch Jun. 3 at 3:08 PM
$TBPH surges 22% on royalty sale! 🚀💰 Theravance announced a $225 million cash deal with $GSK for its remaining royalty interest in Trelegy Ellipta, plus potential $150 million milestone payments. This rally follows the stock's 18.5% YTD performance against industry decline. Full details here 👉 https://www.zacks.com/commentary/2483631/tbph-to-sell-remaining-trelegy-royalty-interest-to-gsk-stock-rises?cid=sm-stocktwits-2-2483631-body&ADID=SYND_STOCKTWITS_TWEET_2_2483631_BODY
0 · Reply
PenkeTrading
PenkeTrading Jun. 3 at 1:30 PM
I found you an Overbought RSI (Relative Strength Index) on the daily chart of Theravance Biopharma Inc. Is that bullish or bearish? $TBPH #RsiOverbought #NASDAQ
0 · Reply
GSP
GSP Jun. 3 at 1:11 PM
0 · Reply
BearTamerTrading
BearTamerTrading Jun. 2 at 8:51 PM
Profit Secured🔒💰🔒 If you tuned into my live YouTube trading session this morning and/or you are a member of the discord “Capital Conspiracy Trading” you would have received our alert🚨before this play took off. Subscribe to my channel on YouTube so you don’t miss out. Also consider our discord group for an even higher earning potential. Thank you for the love & support on Webull & Stocktwits. https://www.youtube.com/live/AwEXxMilFAQ?si=coS54X8d5DiFfbr_ $BMGL $NIVF $TBPH $INM $RVYL
1 · Reply
mebanks
mebanks Jun. 2 at 10:23 AM
$TBPH saying that cash is king, lets see how the market reacts (Shs Float 45.85M based on Finviz)
0 · Reply
DonCorleone77
DonCorleone77 Jun. 2 at 10:14 AM
$GSK $TBPH Theravance to sell remaining royalty interest in Trelegy to GSK for $225M Theravance Biopharma (TBPH) announced that it has entered into a definitive agreement to sell its remaining royalty interest in net sales of Trelegy Ellipta to GSK (GSK) for $225M in cash. Theravance Biopharma's economic interest in Trelegy originates from a 2002 collaboration agreement with GSK, in which Theravance Biopharma's predecessor pooled with GSK its long-acting beta agonist assets in exchange for milestones and royalties on LABA-containing combination products subsequently developed and commercialized by GSK, including Trelegy. In 2022, Theravance Biopharma sold its economic interest in the Trelegy royalties to Royalty Pharma in exchange for $1.1B upfront and potential sales related milestone payments of up to $250M in the aggregate, while retaining the right to receive 85% of Trelegy royalties for sales of Trelegy from and after 2029 and 2031. Under the terms of the agreement, Theravance Biopharma will receive $225M in cash for the sale of the Outer Year Royalties. The Company retains its right to receive up to $150 million in remaining Trelegy sales related milestones in 2025 and 2026 from Royalty Pharma: $50M if FY 2025 global net sales reach ~$3.41B; $100M if FY 2026 global net sales reach ~$3.51B; Theravance Biopharma's financial guidance for 2025 remains unchanged. This transaction represents the first outcome of the ongoing efforts of the Strategic Review Committee of the Board of Directors. Theravance Biopharma announced on November 12, 2024, that the Board of Directors had formed the Committee, composed entirely of independent directors, to assess all strategic alternatives available to the Company. The Company remains focused on disciplined capital allocation and returning excess cash to shareholders. The Committee will continue to evaluate a range of alternatives to further enhance shareholder value, though there can be no assurance that additional transactions will occur.
0 · Reply
Estimize
Estimize May. 13 at 8:00 PM
Wall St is expecting -0.25 EPS for $TBPH Q2 [Reporting 08/11 AMC] http://www.estimize.com/intro/tbph?chart=historical&metric_name=eps&utm_c
0 · Reply
ZacksResearch
ZacksResearch May. 9 at 3:56 PM
$TBPH reports weaker-than-expected first-quarter 2025 results. Collaboration revenues from Viatris rise year over year. To check full the results, click here: https://www.zacks.com/stock/news/2466366/theravances-q1-loss-wider-than-expected-revenues-rise-yy?cid=sm-stocktwits-2-2466366-teaser&ADID=SYND_STOCKTWITS_TWEET_2_2466366_TEASER
0 · Reply
Latest News on TBPH
Theravance Biopharma, Inc. (TBPH) Q3 2024 Earnings Call Transcript

Nov 12, 2024, 10:46 PM EST - 8 months ago

Theravance Biopharma, Inc. (TBPH) Q3 2024 Earnings Call Transcript


Theravance: Positive Findings Boost Ampreloxetine Development

Sep 9, 2023, 11:49 AM EDT - 1 year ago

Theravance: Positive Findings Boost Ampreloxetine Development


JarvisFlow
JarvisFlow Jun. 17 at 11:30 AM
Jones Trading updates rating for Theravance Biopharma ( $TBPH ) to Buy, target set at 24.
0 · Reply
ZacksResearch
ZacksResearch Jun. 3 at 4:41 PM
$TBPH pops 22% on $225M royalty sale to GSK 🔥 Theravance is offloading its last chunk of Trelegy royalties — locking in major cash as part of the deal. What this means for the future of TBPH 👉 https://www.zacks.com/stock/news/2483631/tbph-to-sell-remaining-trelegy-royalty-interest-to-gsk-stock-rises?cid=sm-stocktwits-2-2483631-teaser&ADID=SYND_STOCKTWITS_TWEET_2_2483631_TEASER
0 · Reply
ZacksResearch
ZacksResearch Jun. 3 at 3:08 PM
$TBPH surges 22% on royalty sale! 🚀💰 Theravance announced a $225 million cash deal with $GSK for its remaining royalty interest in Trelegy Ellipta, plus potential $150 million milestone payments. This rally follows the stock's 18.5% YTD performance against industry decline. Full details here 👉 https://www.zacks.com/commentary/2483631/tbph-to-sell-remaining-trelegy-royalty-interest-to-gsk-stock-rises?cid=sm-stocktwits-2-2483631-body&ADID=SYND_STOCKTWITS_TWEET_2_2483631_BODY
0 · Reply
PenkeTrading
PenkeTrading Jun. 3 at 1:30 PM
I found you an Overbought RSI (Relative Strength Index) on the daily chart of Theravance Biopharma Inc. Is that bullish or bearish? $TBPH #RsiOverbought #NASDAQ
0 · Reply
GSP
GSP Jun. 3 at 1:11 PM
0 · Reply
BearTamerTrading
BearTamerTrading Jun. 2 at 8:51 PM
Profit Secured🔒💰🔒 If you tuned into my live YouTube trading session this morning and/or you are a member of the discord “Capital Conspiracy Trading” you would have received our alert🚨before this play took off. Subscribe to my channel on YouTube so you don’t miss out. Also consider our discord group for an even higher earning potential. Thank you for the love & support on Webull & Stocktwits. https://www.youtube.com/live/AwEXxMilFAQ?si=coS54X8d5DiFfbr_ $BMGL $NIVF $TBPH $INM $RVYL
1 · Reply
mebanks
mebanks Jun. 2 at 10:23 AM
$TBPH saying that cash is king, lets see how the market reacts (Shs Float 45.85M based on Finviz)
0 · Reply
DonCorleone77
DonCorleone77 Jun. 2 at 10:14 AM
$GSK $TBPH Theravance to sell remaining royalty interest in Trelegy to GSK for $225M Theravance Biopharma (TBPH) announced that it has entered into a definitive agreement to sell its remaining royalty interest in net sales of Trelegy Ellipta to GSK (GSK) for $225M in cash. Theravance Biopharma's economic interest in Trelegy originates from a 2002 collaboration agreement with GSK, in which Theravance Biopharma's predecessor pooled with GSK its long-acting beta agonist assets in exchange for milestones and royalties on LABA-containing combination products subsequently developed and commercialized by GSK, including Trelegy. In 2022, Theravance Biopharma sold its economic interest in the Trelegy royalties to Royalty Pharma in exchange for $1.1B upfront and potential sales related milestone payments of up to $250M in the aggregate, while retaining the right to receive 85% of Trelegy royalties for sales of Trelegy from and after 2029 and 2031. Under the terms of the agreement, Theravance Biopharma will receive $225M in cash for the sale of the Outer Year Royalties. The Company retains its right to receive up to $150 million in remaining Trelegy sales related milestones in 2025 and 2026 from Royalty Pharma: $50M if FY 2025 global net sales reach ~$3.41B; $100M if FY 2026 global net sales reach ~$3.51B; Theravance Biopharma's financial guidance for 2025 remains unchanged. This transaction represents the first outcome of the ongoing efforts of the Strategic Review Committee of the Board of Directors. Theravance Biopharma announced on November 12, 2024, that the Board of Directors had formed the Committee, composed entirely of independent directors, to assess all strategic alternatives available to the Company. The Company remains focused on disciplined capital allocation and returning excess cash to shareholders. The Committee will continue to evaluate a range of alternatives to further enhance shareholder value, though there can be no assurance that additional transactions will occur.
0 · Reply
Estimize
Estimize May. 13 at 8:00 PM
Wall St is expecting -0.25 EPS for $TBPH Q2 [Reporting 08/11 AMC] http://www.estimize.com/intro/tbph?chart=historical&metric_name=eps&utm_c
0 · Reply
ZacksResearch
ZacksResearch May. 9 at 3:56 PM
$TBPH reports weaker-than-expected first-quarter 2025 results. Collaboration revenues from Viatris rise year over year. To check full the results, click here: https://www.zacks.com/stock/news/2466366/theravances-q1-loss-wider-than-expected-revenues-rise-yy?cid=sm-stocktwits-2-2466366-teaser&ADID=SYND_STOCKTWITS_TWEET_2_2466366_TEASER
0 · Reply
Armonica423
Armonica423 May. 7 at 2:09 AM
$TBPH CYDY
0 · Reply
Yukinvestor
Yukinvestor May. 2 at 5:07 PM
$TBPH That catalysts in May 9 significant mover here?
0 · Reply
PenkeTrading
PenkeTrading May. 2 at 2:13 PM
I found you an Overbought RSI (Relative Strength Index) on the daily chart of Theravance Biopharma Inc. Is that bullish or bearish? $TBPH #RsiOverbought #NASDAQ
0 · Reply
Rage_Against_The_Machine
Rage_Against_The_Machine Apr. 24 at 10:02 AM
$TBPH sets Q1 earnings call for May 8 - same day we'll see if their 'Medicines That Make a Difference' can make a difference for shareholders. With cash dwindling to $37.8M and ampreloxetine data looming, this update could be pivotal. Pro tip: brew extra coffee for the 5pm ET call. https://www.prnewswire.com/news-releases/theravance-biopharma-to-report-first-quarter-2025-financial-results-on-may-8-2025-302436877.html
0 · Reply
MaxAfns
MaxAfns Apr. 20 at 1:10 PM
$TBPH https://x.com/biotechtvhq/status/1912178873699324024?s=46
0 · Reply
NVDAMillionaire
NVDAMillionaire Mar. 29 at 9:20 PM
Watching $TBPH closely. Ampreloxetine CYPRESS study could be game-changer for MSA patients. Potential FDA approval looking promising. Earnings could surprise. compelling writeup: https://beyondspx.com/article/theravance-biopharma-tbph-executing-on-key-value-drivers-amid-a-transformative-period
0 · Reply
JarvisFlow
JarvisFlow Feb. 27 at 2:12 PM
HC Wainwright & Co. has updated their rating for Theravance Biopharma ($TBPH) to Buy with a price target of 15.
0 · Reply
Estimize
Estimize Feb. 12 at 9:03 PM
Wall St is expecting -0.22 EPS for $TBPH Q1 [Reporting 05/13 AMC] http://www.estimize.com/intro/tbph?chart=historical&metric_name=eps&utm_c
0 · Reply
indievestments
indievestments Jan. 27 at 7:23 PM
$TBPH more volume on the March 12.5c. this co is in middle of strategic review.
0 · Reply
indievestments
indievestments Jan. 24 at 8:24 PM
$TBPH what is going on here? GSK buyout?
1 · Reply
PenkeTrading
PenkeTrading Jan. 17 at 7:50 AM
I found you an Oversold RSI (Relative Strength Index) on the daily chart of Theravance Biopharma Inc. Is that bullish or bearish? $TBPH #RsiOversold #NASDAQ
0 · Reply
StockAutoPro
StockAutoPro Dec. 23 at 10:30 PM
$TBPH: Theravance Biopharma excels in respiratory treatments. Buy at $9.79 target $15. Recent trial successes boost investor confidence.
0 · Reply